Atlas Trials

Comparing Dosing Intervals of Nivolumab or Pembrolizumab in Locally Advanced or Metastatic Cancers

Clinical trial NCT04295863 · RECRUITING

Trial details

NCT number
NCT04295863
Sponsor
University of Chicago
Status
RECRUITING
Phase
Phase 1
Study type
INTERVENTIONAL
Metastatic Cancer
Start date
2020-06-25
Primary completion
2026-04-12
Enrollment
264

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.